In short
Currently, there is 1 ongoing clinical trial investigating treatments for relapsing pancreatitis. This trial is exploring whether simvastatin, a medication commonly used to lower cholesterol, can help prevent recurrent episodes of pancreatic inflammation. The study is being conducted in Spain and focuses on patients who have experienced multiple episodes of pancreatitis.
Clinical trial locations
Study on Simvastatin for Preventing Recurrent Pancreatitis in Patients
This clinical trial is investigating whether simvastatin can help prevent recurrent episodes in people who have experienced repeated pancreatic inflammation. The pancreas is an important organ involved in digestion, and when it becomes inflamed, it can cause significant pain and other complications. While simvastatin is traditionally used to lower cholesterol levels, researchers are exploring its potential benefits in reducing the frequency of pancreatitis attacks.
Who can participate:
- Adults aged 18 years or older
- People who have had at least 2 episodes of acute pancreatitis or episodes of chronic pancreatitis
- Individuals willing to provide written consent to participate
Who cannot participate:
- Patients with a history of allergic reactions to simvastatin or similar medications
- People currently taking medications that interact negatively with simvastatin
- Patients with liver disease or kidney disease
- Women who are pregnant or breastfeeding
- Patients who have recently had a heart attack or stroke
- People with uncontrolled diabetes
- Individuals already participating in another clinical trial
What the trial involves:
Participants will be randomly assigned to receive either simvastatin or a placebo (an inactive substance that looks like the medication but contains no active ingredient). This is a triple-blind study, meaning that neither the participants, healthcare providers, nor researchers will know who is receiving the actual medication. This design helps ensure that the results are unbiased and reliable.
The treatment period lasts up to 12 months, during which participants take the medication orally as a film-coated tablet. Throughout the study, researchers will monitor participants for new episodes of pancreatitis and track other health changes such as the development of diabetes or pancreatic insufficiency, the severity of any pancreatitis episodes that do occur, and the number of hospital visits due to abdominal pain.
Trial medication:
The investigational drug being tested is simvastatin, a medication that belongs to a class of drugs called statins. While statins are primarily used to lower cholesterol and reduce the risk of heart disease by inhibiting an enzyme involved in cholesterol production in the liver, this study aims to determine whether simvastatin can also reduce the frequency of recurrent pancreatitis attacks.
Main goal:
The primary objective of this trial is to compare the number of new pancreatitis episodes between those taking simvastatin and those taking the placebo. Additional goals include assessing whether simvastatin helps prevent the development of new health complications, reduces the severity of episodes, and decreases the need for hospital care related to abdominal pain.
Summary
There is currently one clinical trial actively investigating treatment options for relapsing pancreatitis. This trial is being conducted in Spain and focuses on evaluating simvastatin, a medication typically used for cholesterol management, as a potential preventive treatment for recurrent pancreatic inflammation. The study uses a rigorous triple-blind design and will follow participants for up to 12 months to assess whether simvastatin can reduce the frequency and severity of pancreatitis episodes. This research could provide valuable insights into new approaches for managing this painful and potentially debilitating condition.
